EYPT
Income statement / Annual
Last year (2024), EyePoint Pharmaceuticals, Inc.'s total revenue was $43.27 M,
a decrease of 5.97% from the previous year.
In 2024, EyePoint Pharmaceuticals, Inc.'s net income was -$130.87 M.
See EyePoint Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
| Operating Revenue |
$43.27 M |
$46.02 M |
$41.40 M |
$36.94 M |
$34.44 M |
$20.37 M |
$2.96 M |
$7.54 M |
$1.62 M |
$26.57 M |
| Cost of Revenue |
$3.71 M
|
$4.63 M
|
$8.33 M
|
$8.18 M
|
$5.82 M
|
$2.69 M
|
$18.50 M
|
$0.00
|
$815,000.00
|
$14.38 M
|
| Gross Profit |
$39.56 M
|
$41.39 M
|
$33.08 M
|
$28.76 M
|
$28.61 M
|
$17.68 M
|
-$15.54 M
|
$7.54 M
|
$805,000.00
|
$12.18 M
|
| Gross Profit Ratio |
0.91
|
0.9
|
0.8
|
0.78
|
0.83
|
0.87
|
-5.25
|
1
|
0.5
|
0.46
|
| Research and Development Expenses |
$132.93 M
|
$64.66 M
|
$49.64 M
|
$28.50 M
|
$17.42 M
|
$15.37 M
|
$16.18 M
|
$14.88 M
|
$14.38 M
|
$12.09 M
|
| General & Administrative Expenses |
$52.36 M
|
$40.10 M
|
$34.82 M
|
$25.58 M
|
$20.73 M
|
$17.94 M
|
$11.55 M
|
$11.24 M
|
$9.01 M
|
$8.06 M
|
| Selling & Marketing Expenses |
$131,000.00
|
$11.69 M
|
$25.51 M
|
$27.50 M
|
$25.29 M
|
$29.77 M
|
$1.51 M
|
$1.51 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$52.49 M
|
$51.79 M
|
$60.32 M
|
$53.08 M
|
$46.02 M
|
$47.71 M
|
$13.06 M
|
$11.24 M
|
$9.01 M
|
$8.06 M
|
| Other Expenses |
$0.00
|
$0.00
|
$2.05 M
|
$2.46 M
|
$2.46 M
|
$2.46 M
|
$14.84 M
|
$8.31 M
|
$13.98 M
|
$3,000.00
|
| Operating Expenses |
$185.42 M
|
$115.05 M
|
$112.02 M
|
$84.04 M
|
$65.90 M
|
$65.54 M
|
$29.24 M
|
$26.12 M
|
$23.39 M
|
$20.14 M
|
| Cost And Expenses |
$189.13 M
|
$121.09 M
|
$120.34 M
|
$92.22 M
|
$71.73 M
|
$68.23 M
|
$29.24 M
|
$26.12 M
|
$23.39 M
|
$20.14 M
|
| Interest Income |
$15.09 M
|
$6.95 M
|
$2.13 M
|
$292,000.00
|
$58,000.00
|
$1.05 M
|
$101,000.00
|
$91,000.00
|
$72,000.00
|
$19,000.00
|
| Interest Expense |
$14,000.00
|
$1.25 M
|
$3.19 M
|
$5.50 M
|
$7.26 M
|
$6.18 M
|
$720,000.00
|
$720,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.54 M
|
$464,000.00
|
$2.45 M
|
$2.77 M
|
$2.65 M
|
$2.60 M
|
$2.65 M
|
$815,000.00
|
$815,000.00
|
$882,000.00
|
| EBITDA |
-$129.23 M |
-$69.00 M |
-$96.62 M |
-$50.15 M |
-$35.49 M |
-$48.01 M |
-$36.99 M |
-$18.58 M |
-$17.67 M |
-$20.87 M |
| EBITDA Ratio |
-2.99
|
-1.5
|
-1.81
|
-1.42
|
-1.01
|
-2.18
|
-8.84
|
-2.46
|
-13.44
|
0.24
|
| Operating Income Ratio |
-3.37
|
-1.63
|
-1.91
|
-1.5
|
-1.08
|
-2.35
|
-8.87
|
-2.46
|
-13.44
|
0.24
|
| Total Other Income/Expenses Net |
$15.07 M
|
$4.36 M
|
-$2.62 M
|
-$3.14 M
|
-$8.10 M
|
-$8.93 M
|
-$63.17 M
|
-$26.90 M
|
$91,000.00
|
$72,000.00
|
| Income Before Tax |
-$130.78 M
|
-$70.71 M
|
-$102.25 M
|
-$58.42 M
|
-$45.39 M
|
-$56.79 M
|
-$53.17 M
|
-$18.49 M
|
-$21.70 M
|
$6.44 M
|
| Income Before Tax Ratio |
-3.02
|
-1.54
|
-2.47
|
-1.58
|
-1.32
|
-2.79
|
-17.96
|
-2.45
|
-13.4
|
0.24
|
| Income Tax Expense |
$90,000.00
|
$83,000.00
|
$22.26 M
|
$5.50 M
|
$7.26 M
|
$6.18 M
|
-$25.56 M
|
-$815,000.00
|
-$155,000.00
|
$96,000.00
|
| Net Income |
-$130.87 M
|
-$70.80 M
|
-$124.51 M
|
-$63.92 M
|
-$52.65 M
|
-$62.97 M
|
-$53.17 M
|
-$18.49 M
|
-$21.55 M
|
$6.35 M
|
| Net Income Ratio |
-3.02
|
-1.54
|
-3.01
|
-1.73
|
-1.53
|
-3.09
|
-17.96
|
-2.45
|
-13.3
|
0.24
|
| EPS |
-2.32 |
-1.82 |
-3.34 |
-2.22 |
-4.1 |
-6.04 |
-11.5 |
-5.23 |
-6.81 |
2.16 |
| EPS Diluted |
-2.32 |
-1.82 |
-3.34 |
-2.22 |
-4.1 |
-6.04 |
-11.5 |
-5.23 |
-6.81 |
2.08 |
| Weighted Average Shares Out |
$56.30 M
|
$38.90 M
|
$37.32 M
|
$28.76 M
|
$12.84 M
|
$10.43 M
|
$4.62 M
|
$3.53 M
|
$3.16 M
|
$2.94 M
|
| Weighted Average Shares Out Diluted |
$56.30 M
|
$38.90 M
|
$37.32 M
|
$28.76 M
|
$12.84 M
|
$10.43 M
|
$4.62 M
|
$3.53 M
|
$3.16 M
|
$3.06 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
